NEWS DETAIL

CPX-351 (Liposomal Cytarabine dan Daunorubicin) berbanding venetoclax serta terapi agen hipometilasi dalam leukemia myeloid akut yang baru didiagnosis: perbandingan retrospektif yang melibatkan 600 pesakit Mayo Clinic | Jurnal Kanser Darah – Nature

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving…

Maklumat Perubatan

Kandungan penuh artikel

The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p

Produk Berkaitan Artikel Ini

Produk ini dipadankan secara automatik berdasarkan tajuk, ringkasan, dan kandungan artikel.

Soalan Lazim

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Venetoclax – Beli dalam talian VECLADX Venetoclax 100mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat